Fulvestrant in the paliative treatment of hormone-sensitive breast cancer

Abstract

There is strong evidence that endocrine therapy is the preferred option for hormone receptor positive disease according to ABC1 and St. Gallen recommendation. Treatment choice should take into account at least these factors: biology of tumor, sites of metastases, symptoms, performance status; co-morbidities (including organ dysfunctions); and patient preference. The preferred hormone palliative therapy is based on menopausal status. A description of the patient with metastatic breast cancer who during the using of fulvestrant has been reached the long-lasting remission of metastatic lesions.